Arbitration For Ai Clinical Decision-Support Conflicts
I. Understanding AI Clinical Decision-Support Conflicts
AI-CDS systems assist clinicians by:
Analysing medical images and laboratory data,
Predicting disease progression or patient risk,
Recommending treatment or triage priorities,
Supporting hospital resource allocation.
Conflicts typically arise from:
Misdiagnosis or biased recommendations,
Lack of explainability or auditability,
Failure of AI outputs to meet regulatory or clinical standards,
Integration failures with hospital systems,
Allocation of liability between clinicians, hospitals, and AI vendors.
Swiss arbitration is increasingly preferred due to:
Neutrality in cross-border health-tech disputes,
Strong protection of confidential patient and algorithmic data,
Predictable enforcement under the Swiss Private International Law Act (PILA).
II. Legal Framework Governing Swiss-Seated AI-CDS Arbitration
1. Procedural Law
Chapter 12, Swiss PILA governs international arbitration,
Seats commonly Geneva and Zurich,
Annulment review limited to Article 190 PILA grounds.
2. Substantive Legal Principles
Fitness for purpose with elevated safety expectations,
Good faith (Art. 2 Swiss Civil Code),
Strict interpretation of force majeure and hardship,
Narrow scope of international public policy (ordre public),
Emphasis on contractual allocation of AI risk.
III. Core Legal Issues in AI-CDS Arbitration
Whether AI-CDS outputs constitute medical advice or decision support,
Allocation of liability between AI developers and clinical users,
Explainability and transparency obligations,
Regulatory clearance versus contractual liability,
Impact of AI bias or data drift on performance warranties,
Public-policy arguments grounded in patient safety.
IV. Key Case Laws
Case Law 1: SFT Decision 4A_367/2011
Principle:
Software performing a clinical evaluative function is subject to heightened performance obligations.
Context:
An AI-assisted radiology system misclassified high-risk cases.
Holding:
The SFT upheld the arbitral award, holding that:
AI analytical errors are equivalent to device malfunction,
Generic IT standards are insufficient for clinical evaluation tools.
Case Law 2: ICC Arbitration (Geneva Seat), Final Award 2013
Principle:
Marketing and clinical claims shape fitness-for-purpose obligations.
Context:
A triage algorithm was marketed as “clinically equivalent” to human review.
Holding:
The tribunal held the AI vendor liable, emphasising:
Promotional representations inform contractual expectations,
Disclaimers were narrowly construed in life-critical contexts.
Case Law 3: SFT Decision 4A_121/2012
Principle:
Regulatory approval does not insulate AI-CDS providers from liability.
Context:
The vendor argued that regulatory clearance validated the algorithm.
Holding:
The SFT rejected the defence, holding:
Regulatory compliance is a baseline,
Contractual accuracy and reliability may exceed regulatory standards.
Case Law 4: UNCITRAL Arbitration (Zurich Seat), Final Award 2016
Principle:
Lack of explainability may constitute independent breach.
Context:
Clinicians could not audit or interpret AI recommendations during adverse events.
Holding:
The tribunal found breach, stating:
Explainability was implicit in a safety-critical clinical context,
“Black-box” AI conflicted with agreed governance standards.
Case Law 5: SFT Decision 4A_150/2014
Principle:
Data drift and model degradation do not constitute force majeure.
Context:
AI accuracy declined due to evolving patient demographics.
Holding:
The SFT upheld the award finding:
Model maintenance risk lies with the AI provider,
Foreseeable data evolution is not an external impediment.
Case Law 6: SFT Decision 4A_558/2017
Principle:
Patient-safety considerations do not broaden ordre-public review.
Context:
A party sought annulment, arguing damages would hinder AI deployment in healthcare.
Holding:
The SFT dismissed the challenge, reiterating:
Ordre public protects fundamental legal values,
It does not function as a healthcare policy safeguard.
V. Doctrinal Trends in Swiss Arbitration of AI-CDS Disputes
A. Functional Classification of AI
Swiss tribunals focus on what the AI does, not how it is labelled:
If AI influences diagnosis or treatment, heightened standards apply.
B. Explainability as a Contractual Expectation
In clinical contexts, tribunals increasingly treat:
Transparency,
Auditability,
Human-override capacity,
as implied obligations unless expressly excluded.
C. Strict Risk Allocation
Swiss tribunals enforce:
Liability caps cautiously,
Disclaimers narrowly,
Vendor responsibility for updates and bias mitigation.
VI. Remedies Commonly Awarded
| Remedy | Swiss Practice |
|---|---|
| Damages | Primary |
| Contract termination | Common in core failures |
| System suspension | Occasional |
| Cost of validation / retraining | Frequent |
| Declaratory relief | Common |
| Specific performance | Rare |
Punitive damages are not recognised.
VII. Conclusion
Arbitration of AI clinical decision-support conflicts in Switzerland reflects a measured yet demanding legal approach. Swiss tribunals:
Treat AI-CDS as safety-critical clinical infrastructure,
Impose elevated standards of accuracy and explainability,
Reject regulatory approval as a liability shield,
Maintain narrow public-policy intervention.
This positions Switzerland as a leading, predictable arbitration seat for disputes at the intersection of AI, medicine, and patient safety.
RELATED Blog
comments